DD29937A - - Google Patents
Info
- Publication number
- DD29937A DD29937A DD29937DA DD29937A DD 29937 A DD29937 A DD 29937A DD 29937D A DD29937D A DD 29937DA DD 29937 A DD29937 A DD 29937A
- Authority
- DD
- German Democratic Republic
Links
Publications (1)
Publication Number | Publication Date |
---|---|
DD29937A true DD29937A (en) |
Family
ID=236065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD29937D DD29937A (en) |
Country Status (1)
Country | Link |
---|---|
DD (1) | DD29937A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7851636B2 (en) | 2004-01-06 | 2010-12-14 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
-
0
- DD DD29937D patent/DD29937A/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7851636B2 (en) | 2004-01-06 | 2010-12-14 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE45183E1 (en) | Heteroaryl-ureas and their use as glucokinase activators | |
AU2015264021A1 (en) | Imidazole derivatives as formyl peptide receptor modulators | |
WO2023225300A2 (en) | Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto | |
DD29937A (en) |